Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2023 edition) / 中华肿瘤杂志
Chinese Journal of Oncology
; (12): 575-583, 2023.
Article
Dans Zh
| WPRIM
| ID: wpr-980725
Responsable en Bibliothèque :
WPRO
ABSTRACT
Chemotherapy-induced neutropenia (CIN) is a common hematological adverse events and dose-limiting toxicities of chemotherapy. CIN may lead to dose reduction and delay of chemotherapeutic agents, febrile neutropenia and severe infection, which results in increased treatment cost, reduced efficacy of chemotherapy, and even life-threatening morbidities. Assessment of risk of CIN, early detection of FN and infection, and proper prevention and treatment play a crucial role in reducing the occurrence of CIN-related morbidities, improving patient treatment safety and anticancer efficacy. Based on evidence and expert opinion, the expert committee of Chinese Anti-Cancer Association issued "the consensus on diagnosis and treatment of chemotherapy-induced neutropenia in China (2023 edition)", which is an update version of the 2019 edition, aiming to provide reference for the diagnosis and treatment of CIN for Chinese oncologists.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Protocoles de polychimiothérapie antinéoplasique
/
Facteur de stimulation des colonies de granulocytes
/
Consensus
/
Tumeurs
/
Neutropénie
/
Antinéoplasiques
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Chinese Journal of Oncology
Année:
2023
Type:
Article